Health Canada Issues Nationwide Recall for JAMP-Pregabalin Over Dosage Error
Health Canada has issued a nationwide recall for one lot of JAMP-Pregabalin 50 mg capsules after it was discovered that some bottles may mistakenly contain 150 mg capsules, posing a serious overdose risk.
The affected lot (Lot #2305012747, DIN 02435985, expiry date August 2026) is being voluntarily recalled by JAMP Pharma Corp. due to the potential for patients to unintentionally take a higher dose than prescribed. According to Health Canada’s safety alert, this dosage error could result in serious and potentially life-threatening health effects.
JAMP-Pregabalin is commonly prescribed to adults for nerve pain related to diabetes, shingles, spinal cord injuries, and fibromyalgia. Health Canada warns that an overdose of pregabalin can cause severe symptoms such as confusion, agitation, sleepiness, mood swings, depression, seizures, and even cardiac or respiratory complications—especially if taken alongside other central nervous system depressants like opioids.
Consumers are urged to inspect their medication. Authentic 50 mg capsules are white and marked with “PG” and “50” in black ink. Any capsules marked “PG” and “150” should not be taken and must be returned to the pharmacy immediately.
Patients are strongly advised not to stop taking the medication abruptly without consulting a healthcare provider, as sudden withdrawal can lead to symptoms including anxiety, insomnia, nausea, and seizures.
Health-care providers are asked to verify the contents of JAMP-Pregabalin 50 mg bottles before dispensing.
Health Canada is overseeing the recall process and monitoring the company’s investigation to ensure corrective actions are taken.
For more information, consumers can contact JAMP Pharma Corp. at 1-866-399-9091 ext. 501 or by email at custjamp@jamppharma.com.
